1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
ADDvise Group AB (publ)

ADDvise Group AB (publ)

ADDV-B.ST
ADDvise Group AB (publ)SE flagStockholm Stock Exchange
1.73
SEK
+0.01
- -
1.05BMarket Cap
ADDvise Group AB (publ)
ADDV-B.ST
(Stockholm Stock Exchange)

Recent

price

1.73

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
2.51
3.68
5.07
5.6
2.46
2.55
1.83
1.59
2.57
1.66
1.53
1.34
2.21
3.05
8.49
3.22
5.67
Revenue per Share
-0.54
-0.02
-0.18
-0.21
-0.08
-0.19
- -
-0.04
-0.01
0.02
0.06
0.01
0.19
0.23
0.46
0.01
-0.14
Basic EPS, GAAP
-0.3
0.02
0.27
-1.48
-0.33
-0.18
-0.34
-0.16
-0.04
0.03
0.24
0.02
0.22
0.35
0.07
0.28
0.31
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.01
- -
- -
- -
- -
- -
Dividend per Share
-0.17
0.66
0.5
0.3
0.05
-0.01
-0.11
-0.11
-0.17
-0.04
0.03
0.04
0.22
0.44
1.48
- -
- -
Book Value per Share
-0.37
0.12
-0.91
-1.83
-1.04
-1.28
-0.71
-0.68
-1.08
-0.58
-0.46
-0.56
-1.84
-3.6
-7.56
-1.93
-3.56
Tangible Book Value per Share
9
14
20
21
56
58
107
150
104
210
235
347
430
450
197
499
294
Basic Weighted Avg Shares
22
50
100
120
138
147
195
240
268
350
358
466
952
1,373
1,671
1,606
1,665
Sales/Revenue/Turnover
-20.97
-1.14
-1.76
1.04
1.92
-4.27
1.27
3.59
3.74
4.69
9.56
9.28
16.1
22.7
17.53
14.45
15.25
Operating Margin (%)
1
1
3
2
2
3
4
5
6
12
12
14
28
109
86
107
108
Depreciation Expense
-5
- -
-4
-4
-5
-11
- -
-6
-1
4
15
3
81
104
90
3
-40
Net Income, GAAP
- -
- -
- -
- -
- -
- -
64.57
- -
- -
- -
18.03
63.37
24.91
37.01
37.73
92.76
406.92
Effective Tax Rate (%)
-21.41
-0.55
-3.58
-3.66
-3.45
-7.57
0.19
-2.42
-0.4
1.16
4.08
0.6
8.52
7.54
5.39
0.19
-2.4
Profit Margin (%)
-1
1
- -
-4
13
3
12
-2
11
-1
12
375
146
134
282
-72
-100
Working Capital
1
1
22
39
72
84
94
116
137
144
142
525
744
1,523
1,736
944
965
LT Debt
4
9
10
11
15
4
46
49
51
84
91
247
493
613
835
1,064
1,054
Total Equity
- -
- -
- -
- -
- -
- -
0.65
- -
- -
- -
9.88
2.89
10.93
11.07
7.45
0.68
-31.28
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
4.32
- -
- -
- -
14.56
2.88
16.02
12.23
9.74
0.19
-2.61
Return on Capital (%)
- -
- -
-38.03
-53.92
-101.44
- -
- -
- -
- -
- -
- -
29.83
149.67
70.12
36.69
2.13
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
55
56
265
LT Borrowings
1,673
- -
- -
LT Finance Leases
62
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
299
299
606
Market Capitalization
677
233
479

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
893
764
632
Cash, Cash Equivalents & STI
334
277
140
Accounts Receivable, Net
284
258
254
Inventories
131
119
114
Total Current Liabilities
611
512
732
Payables & Accruals
- -
- -
- -
ST Debt
55
56
265
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
142.5%
71.79%
27.44%
Free Cash Flow
317.64%
463.75%
948.51%
Net Income, GAAP
56.22%
525.69%
-96.56%
Sales/Revenue/Turnover
29.71%
39.26%
-3.89%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
310
344
321
397
1,373
2024
413
412
404
442
1,671
2025
424
396
422
- -
1,606

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
0.08
0.01
0.08
0.07
0.23
2024
0.23
0.15
0.06
0.03
0.46
2025
0.13
-0.14
0.01
- -
0.01

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Theralase Technologies Inc. (TLTFF)
Novocure Ltd (NVCR)
Evome Medical Technologies Inc. (LNDZF)
GN Store Nord A/S (GN.CO)
MicroPort NeuroTech Limited (2172.HK)
Pheton Holdings Ltd Class A Ordinary Shares (PTHL)
Business
ADDvise Group AB (publ) is a Sweden-based life science company that supplies comprehensive equipment, medical devices, consumables and services to healthcare facilities, public and private laboratories and research institutions primarily in the Nordic region, Europe, North America and select international markets. Founded in 1989 and headquartered in Stockholm, the company operates through two main business areas, Lab and Healthcare; the Lab segment provides laboratory furnishings, safety ventilation systems, climate rooms, cleanrooms, laboratory apparatus and installation services to the pharmaceutical and life science research industries, while the Healthcare segment offers advanced and conventional medical devices including surgical tables, orthopedic implants, patient monitoring systems and consumables. ADDvise Group employs a decentralized model with multiple subsidiaries such as MRC Systems, ADDvise KEBO and ADDvise Tillquist, pursuing growth via acquisitions to expand geographically and diversify products within the medtech sector. In recent developments, ADDvise completed a rights issue raising approximately SEK 457 million, entered a facilities agreement with Nordea reducing annual financial costs by SEK 56 million, issued new SEK senior unsecured bonds, published a prospectus for bond trading admission on Nasdaq Stockholm, received a SEK 72 million allocation decision and secured significant orders including EUR 2.6 million for cleanroom installation from Rafarm in Greece (delivery Q4 2025) and USD 2.3 million from IPS for life sciences projects; the company also appointed Johan Irwe as CFO, shifted Staffan Torstensson to Head of Healthcare and announced updated long-term financial targets alongside preliminary Q4 2024 results. Shares trade on Nasdaq First North Growth Market under tickers ADDV-A.ST and ADDV-B.ST.